Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM)

被引：5
|
作者：
Nowak, A. K. [1 ]
Millward, M. J. [1 ]
Francis, R. [1 ]
van der Schaaf, A. [1 ]
Musk, A. W. [1 ]
Byrne, M. J. [1 ]
机构：
[1] Sir Charles Gairdner Hosp, Perth, WA, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.8063
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8063
引用
收藏
页数：1
相关论文
共 50 条
  • [1] FINAL RESULTS OF A PHASE II STUDY OF SUNITINIB AS SECOND LINE THERAPY OF MALIGNANT PLEURAL MESOTHELIOMA (MPM)
    Nowak, A. K.
    Francis, R. J.
    Millward, M. J.
    van der Schaaf, A.
    Seguard, T.
    Creaney, J.
    Hasani, A.
    Musk, A. W.
    Byrne, M. J.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (03) : S12 - S12
  • [2] Final results of a phase II study of sunitinib as second- line therapy in malignant pleural mesothelioma (MPM)
    Nowak, A. K.
    Millward, M.
    Francis, R. J.
    Hasani, A.
    van der Schaaf, A. A.
    Seguard, T.
    Musk, A. W.
    Byrne, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural Mesothelioma
    Nowak, Anna K.
    Millward, Michael J.
    Creaney, Jenette
    Francis, Roslyn J.
    Dick, Ian M.
    Hasani, Arman
    van der Schaaf, Agatha
    Segal, Amanda
    Musk, Arthur W.
    Byrne, Michael J.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : 1449 - 1456
  • [4] A RETROSPECTIVE ANALYSIS OF SECOND-LINE CHEMOTHERAPY FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM)
    Bramati, A.
    Moretti, A.
    Garassino, M. C.
    Califano, R.
    Farina, G.
    Lo Dico, M.
    Cinquini, M.
    Michetti, G. N.
    Tiseo, M.
    Zucali, P. A.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S103 - S103
  • [5] A retrospective analysis of second-line chemotherapy for malignant pleural mesothelioma (MPM)
    La Verde, N. M.
    Bramati, A.
    Cinquini, M.
    Tiseo, M.
    Collova, E.
    Michetti, A.
    Lo Dico, M.
    Foliador, A.
    Garassino, M. C.
    Zucaii, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] NGR-hTNF as second-line treatment in malignant pleural mesothelioma (MPM)
    Rossoni, Gilda
    Gregorc, Vanesa
    Vigano, Maria Grazia
    Bulotta, Alessandra
    Ghio, Domenico
    Lambiase, Antonio
    Bordignon, Claudio
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [7] A gentle therapy: Weekly epirubicin, as second-line treatment in elderly patients with malignant pleural mesothelioma (MPM).
    Bollina, Roberto
    Belloni, Paolo
    Pelliccione, Michela
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] GemOx as second-line treatment in a selected population of patients with malignant pleural mesothelioma (MPM)
    Mucciarini, C.
    Masoni, F.
    Giovanardi, F.
    Artioli, F.
    ANNALS OF ONCOLOGY, 2006, 17 : XI85 - XI86
  • [9] Pemetrexed in second-line therapy in patients with malignant pleural mesothelioma
    Serke, M.
    Bauer, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [10] Pemetrexed for malignant pleural mesothelioma: Is it a standard second-line therapy?
    Tamura, Kenji
    Fujiwara, Yasuhiro
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2010, 6 (04) : 248 - 250
12345